Breaking News

Financial Report: Biogen Idec 3Q11

Revenues up 11%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q11   3Q Revenues: $1.3 billion (+11%)   3Q Earnings: $352 million (+38%)   YTD Revenues: $3.7 billion (+6%)    YTD Earnings: $966.5 million (earnings were $626.8 million 3Q10)   Comments: Global in-market sales of Tysabri were $393 million in the quarter (+28%). Avonex sales increased 6% to $682 million. Rituxan revenues from the company’s joint business arrangement with Genentech were $266 million (+3%). Royalties were $52 million in the quarter, up 43%.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters